Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 1.61% 1430 Delayed Quote.8.13%
GLAXOSMITHKLINE 1.91% 16.458 Delayed Quote.9.71%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20P&G's vitamin boost could signal more to come
RE
04/19GLAXOSMITHKLINE : New Gingivitis Study Results from GlaxoSmithKline plc Describe..
AQ
04/19GLAXOSMITHKLINE : An Application for the Trademark "DOVATOR" Has Been Filed by G..
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "DOVIPSA" Filed
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "ABREVA" Filed by GlaxoSmithKline
AQ
04/19GLAXOSMITHKLINE : Reports Summarize Vaccines Study Results from GlaxoSmithKline ..
AQ
04/19GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Describe Findings in Tube..
AQ
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/19NEUROMETRIX : Reports Q1 2018 Financial Results
AQ
More news
News from SeekingAlpha
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/19Novartis Q1 results weigh on pharma stocks 
04/18Glaxo poaches Roche dealmaker signaling commitment to pipeline-boosting trans.. 
04/17Evelo Biosciences Files For U.S. IPO 
04/17JF'S CORE BIOTECH BUYS #11 : Positive News For Several Holdings, A Change To Ben.. 
Financials ( GBP)
Sales 2018 29 850 M
EBIT 2018 8 139 M
Net income 2018 3 877 M
Debt 2018 17 446 M
Yield 2018 5,60%
P/E ratio 2018 17,65
P/E ratio 2019 15,24
EV / Sales 2018 2,96x
EV / Sales 2019 2,85x
Capitalization 70 913 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 15,4  GBP
Spread / Average Target 7,9%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE8.13%99 256
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571